Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement

Douglas R. Sidell; Karthik Balakrishnan; Simon R. Best; Karen Zur; Julia Buckingham; Alessandro De Alarcon; Fuad M. Baroody; Jonathan M. Bock; Emily F. Boss; Charles M. Bower; Paolo Campisi; Sharon F. Chen; Jeffrey M. Clarke; Kevin D. Clarke; Alejandro Cocciaglia; Robin T. Cotton; Giselle Cuestas; Kara L. Davis; Victor H. DeFago; Frederik G. Dikkers; Ines Dossans; Walter Florez; Elizabeth Fox; Aaron D. Friedman; Nazaneen Grant; Osama Hamdi; Norman D. Hogikyan; Kaalan Johnson; Liane B. Johnson; Romaine F. Johnson; Peggy Kelly; Adam M. Klein; Claire M. Lawlor; Nicolas Leboulanger; Alejandro G. Levy; Derek Lam; Greg R. Licameli; Steve Long; David G. Lott; Dayse Manrique; James Scott McMurray; Kara D. Meister; Anna H. Messner; Michael Mohr; Pamela Mudd; Anthony J. Mortelliti; Daniel Novakovic; Julian Ongkasuwan; Shazia Peer; Krysztof Piersiala; Jeremy D. Prager; Seth M. Pransky; Diego Preciado; Tiffany Raynor; Rico N.P.M. Rinkel; Hugo Rodriguez; Verónica P. Rodríguez; John Russell; María Laura Scatolini; Patrick Scheffler; David F. Smith; Lee P. Smith; Marshall E. Smith; Richard J.H. Smith; Abraham Sorom; Amalia Steinberg; John A. Stith; Dana Thompson; Jerome W. Thompson; Patricio Varela; David R. White; Andre M. Wineland; Christina J. Yang; Carlton J. Zdanski; Craig S. Derkay

doi:10.1002/lary.29343

Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement

Douglas R. Sidell, Karthik Balakrishnan, Simon R. Best, Karen Zur, Julia Buckingham, Alessandro De Alarcon, Fuad M. Baroody, Jonathan M. Bock, Emily F. Boss, Charles M. Bower, Paolo Campisi, Sharon F. Chen, Jeffrey M. Clarke, Kevin D. Clarke, Alejandro Cocciaglia, Robin T. Cotton, Giselle Cuestas, Kara L. Davis, Victor H. DeFago, Frederik G. DikkersInes Dossans, Walter Florez, Elizabeth Fox, Aaron D. Friedman, Nazaneen Grant, Osama Hamdi, Norman D. Hogikyan, Kaalan Johnson, Liane B. Johnson, Romaine F. Johnson, Peggy Kelly, Adam M. Klein, Claire M. Lawlor, Nicolas Leboulanger, Alejandro G. Levy, Derek Lam, Greg R. Licameli, Steve Long, David G. Lott, Dayse Manrique, James Scott McMurray, Kara D. Meister, Anna H. Messner, Michael Mohr, Pamela Mudd, Anthony J. Mortelliti, Daniel Novakovic, Julian Ongkasuwan, Shazia Peer, Krysztof Piersiala, Jeremy D. Prager, Seth M. Pransky, Diego Preciado, Tiffany Raynor, Rico N.P.M. Rinkel, Hugo Rodriguez, Verónica P. Rodríguez, John Russell, María Laura Scatolini, Patrick Scheffler, David F. Smith, Lee P. Smith, Marshall E. Smith, Richard J.H. Smith, Abraham Sorom, Amalia Steinberg, John A. Stith, Dana Thompson, Jerome W. Thompson, Patricio Varela, David R. White, Andre M. Wineland, Christina J. Yang, Carlton J. Zdanski, Craig S. Derkay

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Objectives/Hypothesis: The purpose of this study is to develop consensus on key points that would support the use of systemic bevacizumab for the treatment of recurrent respiratory papillomatosis (RRP), and to provide preliminary guidance surrounding the use of this treatment modality. Study Design: Delphi method-based survey series. Methods: A multidisciplinary, multi-institutional panel of physicians with experience using systemic bevacizumab for the treatment of RRP was established. The Delphi method was used to identify and obtain consensus on characteristics associated with systemic bevacizumab use across five domains: 1) patient characteristics; 2) disease characteristics; 3) treating center characteristics; 4) prior treatment characteristics; and 5) prior work-up. Results: The international panel was composed of 70 experts from 12 countries, representing pediatric and adult otolaryngology, hematology/oncology, infectious diseases, pediatric surgery, family medicine, and epidemiology. A total of 189 items were identified, of which consensus was achieved on Patient Characteristics (9), Disease Characteristics (10), Treatment Center Characteristics (22), and Prior Workup Characteristics (18). Conclusion: This consensus statement provides a useful starting point for clinicians and centers hoping to offer systemic bevacizumab for RRP and may serve as a framework to assess the components of practices and centers currently using this therapy. We hope to provide a strategy to offer the treatment and also to provide a springboard for bevacizumab's use in combination with other RRP treatment protocols. Standardized delivery systems may facilitate research efforts and provide dosing regimens to help shape best-practice applications of systemic bevacizumab for patients with early-onset or less-severe disease phenotypes. Level of Evidence: 5 Laryngoscope, 131:E1941–E1949, 2021.

Original language	English (US)
Pages (from-to)	E1941-E1949
Journal	Laryngoscope
Volume	131
Issue number	6
DOIs	https://doi.org/10.1002/lary.29343
State	Published - Jun 2021

Keywords

Avastin
Systemic bevacizumab
consensus

ASJC Scopus subject areas

Otorhinolaryngology

Access to Document

10.1002/lary.29343

Cite this

Sidell, D. R., Balakrishnan, K., Best, S. R., Zur, K., Buckingham, J., De Alarcon, A., Baroody, F. M., Bock, J. M., Boss, E. F., Bower, C. M., Campisi, P., Chen, S. F., Clarke, J. M., Clarke, K. D., Cocciaglia, A., Cotton, R. T., Cuestas, G., Davis, K. L., DeFago, V. H., ... Derkay, C. S. (2021). Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement. Laryngoscope, 131(6), E1941-E1949. https://doi.org/10.1002/lary.29343

Sidell, DR, Balakrishnan, K, Best, SR, Zur, K, Buckingham, J, De Alarcon, A, Baroody, FM, Bock, JM, Boss, EF, Bower, CM, Campisi, P, Chen, SF, Clarke, JM, Clarke, KD, Cocciaglia, A, Cotton, RT, Cuestas, G, Davis, KL, DeFago, VH, Dikkers, FG, Dossans, I, Florez, W, Fox, E, Friedman, AD, Grant, N, Hamdi, O, Hogikyan, ND, Johnson, K, Johnson, LB, Johnson, RF, Kelly, P, Klein, AM, Lawlor, CM, Leboulanger, N, Levy, AG, Lam, D, Licameli, GR, Long, S, Lott, DG, Manrique, D, McMurray, JS, Meister, KD, Messner, AH, Mohr, M, Mudd, P, Mortelliti, AJ, Novakovic, D, Ongkasuwan, J, Peer, S, Piersiala, K, Prager, JD, Pransky, SM, Preciado, D, Raynor, T, Rinkel, RNPM, Rodriguez, H, Rodríguez, VP, Russell, J, Scatolini, ML, Scheffler, P, Smith, DF, Smith, LP, Smith, ME, Smith, RJH, Sorom, A, Steinberg, A, Stith, JA, Thompson, D, Thompson, JW, Varela, P, White, DR, Wineland, AM, Yang, CJ, Zdanski, CJ & Derkay, CS 2021, 'Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement', Laryngoscope, vol. 131, no. 6, pp. E1941-E1949. https://doi.org/10.1002/lary.29343

@article{b546cf53af7d47c0a1f216270f5e4356,

title = "Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement",

abstract = "Objectives/Hypothesis: The purpose of this study is to develop consensus on key points that would support the use of systemic bevacizumab for the treatment of recurrent respiratory papillomatosis (RRP), and to provide preliminary guidance surrounding the use of this treatment modality. Study Design: Delphi method-based survey series. Methods: A multidisciplinary, multi-institutional panel of physicians with experience using systemic bevacizumab for the treatment of RRP was established. The Delphi method was used to identify and obtain consensus on characteristics associated with systemic bevacizumab use across five domains: 1) patient characteristics; 2) disease characteristics; 3) treating center characteristics; 4) prior treatment characteristics; and 5) prior work-up. Results: The international panel was composed of 70 experts from 12 countries, representing pediatric and adult otolaryngology, hematology/oncology, infectious diseases, pediatric surgery, family medicine, and epidemiology. A total of 189 items were identified, of which consensus was achieved on Patient Characteristics (9), Disease Characteristics (10), Treatment Center Characteristics (22), and Prior Workup Characteristics (18). Conclusion: This consensus statement provides a useful starting point for clinicians and centers hoping to offer systemic bevacizumab for RRP and may serve as a framework to assess the components of practices and centers currently using this therapy. We hope to provide a strategy to offer the treatment and also to provide a springboard for bevacizumab's use in combination with other RRP treatment protocols. Standardized delivery systems may facilitate research efforts and provide dosing regimens to help shape best-practice applications of systemic bevacizumab for patients with early-onset or less-severe disease phenotypes. Level of Evidence: 5 Laryngoscope, 131:E1941–E1949, 2021.",

keywords = "Avastin, Systemic bevacizumab, consensus",

author = "Sidell, {Douglas R.} and Karthik Balakrishnan and Best, {Simon R.} and Karen Zur and Julia Buckingham and {De Alarcon}, Alessandro and Baroody, {Fuad M.} and Bock, {Jonathan M.} and Boss, {Emily F.} and Bower, {Charles M.} and Paolo Campisi and Chen, {Sharon F.} and Clarke, {Jeffrey M.} and Clarke, {Kevin D.} and Alejandro Cocciaglia and Cotton, {Robin T.} and Giselle Cuestas and Davis, {Kara L.} and DeFago, {Victor H.} and Dikkers, {Frederik G.} and Ines Dossans and Walter Florez and Elizabeth Fox and Friedman, {Aaron D.} and Nazaneen Grant and Osama Hamdi and Hogikyan, {Norman D.} and Kaalan Johnson and Johnson, {Liane B.} and Johnson, {Romaine F.} and Peggy Kelly and Klein, {Adam M.} and Lawlor, {Claire M.} and Nicolas Leboulanger and Levy, {Alejandro G.} and Derek Lam and Licameli, {Greg R.} and Steve Long and Lott, {David G.} and Dayse Manrique and McMurray, {James Scott} and Meister, {Kara D.} and Messner, {Anna H.} and Michael Mohr and Pamela Mudd and Mortelliti, {Anthony J.} and Daniel Novakovic and Julian Ongkasuwan and Shazia Peer and Krysztof Piersiala and Prager, {Jeremy D.} and Pransky, {Seth M.} and Diego Preciado and Tiffany Raynor and Rinkel, {Rico N.P.M.} and Hugo Rodriguez and Rodr{\'i}guez, {Ver{\'o}nica P.} and John Russell and Scatolini, {Mar{\'i}a Laura} and Patrick Scheffler and Smith, {David F.} and Smith, {Lee P.} and Smith, {Marshall E.} and Smith, {Richard J.H.} and Abraham Sorom and Amalia Steinberg and Stith, {John A.} and Dana Thompson and Thompson, {Jerome W.} and Patricio Varela and White, {David R.} and Wineland, {Andre M.} and Yang, {Christina J.} and Zdanski, {Carlton J.} and Derkay, {Craig S.}",

note = "Publisher Copyright: {\textcopyright} 2021 The American Laryngological, Rhinological and Otological Society, Inc.",

year = "2021",

month = jun,

doi = "10.1002/lary.29343",

language = "English (US)",

volume = "131",

pages = "E1941--E1949",

journal = "Laryngoscope",

issn = "0023-852X",

publisher = "John Wiley and Sons Inc.",

number = "6",

}

TY - JOUR

T1 - Systemic Bevacizumab for Treatment of Respiratory Papillomatosis

T2 - International Consensus Statement

AU - Sidell, Douglas R.

AU - Balakrishnan, Karthik

AU - Best, Simon R.

AU - Zur, Karen

AU - Buckingham, Julia

AU - De Alarcon, Alessandro

AU - Baroody, Fuad M.

AU - Bock, Jonathan M.

AU - Boss, Emily F.

AU - Bower, Charles M.

AU - Campisi, Paolo

AU - Chen, Sharon F.

AU - Clarke, Jeffrey M.

AU - Clarke, Kevin D.

AU - Cocciaglia, Alejandro

AU - Cotton, Robin T.

AU - Cuestas, Giselle

AU - Davis, Kara L.

AU - DeFago, Victor H.

AU - Dikkers, Frederik G.

AU - Dossans, Ines

AU - Florez, Walter

AU - Fox, Elizabeth

AU - Friedman, Aaron D.

AU - Grant, Nazaneen

AU - Hamdi, Osama

AU - Hogikyan, Norman D.

AU - Johnson, Kaalan

AU - Johnson, Liane B.

AU - Johnson, Romaine F.

AU - Kelly, Peggy

AU - Klein, Adam M.

AU - Lawlor, Claire M.

AU - Leboulanger, Nicolas

AU - Levy, Alejandro G.

AU - Lam, Derek

AU - Licameli, Greg R.

AU - Long, Steve

AU - Lott, David G.

AU - Manrique, Dayse

AU - McMurray, James Scott

AU - Meister, Kara D.

AU - Messner, Anna H.

AU - Mohr, Michael

AU - Mudd, Pamela

AU - Mortelliti, Anthony J.

AU - Novakovic, Daniel

AU - Ongkasuwan, Julian

AU - Peer, Shazia

AU - Piersiala, Krysztof

AU - Prager, Jeremy D.

AU - Pransky, Seth M.

AU - Preciado, Diego

AU - Raynor, Tiffany

AU - Rinkel, Rico N.P.M.

AU - Rodriguez, Hugo

AU - Rodríguez, Verónica P.

AU - Russell, John

AU - Scatolini, María Laura

AU - Scheffler, Patrick

AU - Smith, David F.

AU - Smith, Lee P.

AU - Smith, Marshall E.

AU - Smith, Richard J.H.

AU - Sorom, Abraham

AU - Steinberg, Amalia

AU - Stith, John A.

AU - Thompson, Dana

AU - Thompson, Jerome W.

AU - Varela, Patricio

AU - White, David R.

AU - Wineland, Andre M.

AU - Yang, Christina J.

AU - Zdanski, Carlton J.

AU - Derkay, Craig S.

PY - 2021/6

Y1 - 2021/6

N2 - Objectives/Hypothesis: The purpose of this study is to develop consensus on key points that would support the use of systemic bevacizumab for the treatment of recurrent respiratory papillomatosis (RRP), and to provide preliminary guidance surrounding the use of this treatment modality. Study Design: Delphi method-based survey series. Methods: A multidisciplinary, multi-institutional panel of physicians with experience using systemic bevacizumab for the treatment of RRP was established. The Delphi method was used to identify and obtain consensus on characteristics associated with systemic bevacizumab use across five domains: 1) patient characteristics; 2) disease characteristics; 3) treating center characteristics; 4) prior treatment characteristics; and 5) prior work-up. Results: The international panel was composed of 70 experts from 12 countries, representing pediatric and adult otolaryngology, hematology/oncology, infectious diseases, pediatric surgery, family medicine, and epidemiology. A total of 189 items were identified, of which consensus was achieved on Patient Characteristics (9), Disease Characteristics (10), Treatment Center Characteristics (22), and Prior Workup Characteristics (18). Conclusion: This consensus statement provides a useful starting point for clinicians and centers hoping to offer systemic bevacizumab for RRP and may serve as a framework to assess the components of practices and centers currently using this therapy. We hope to provide a strategy to offer the treatment and also to provide a springboard for bevacizumab's use in combination with other RRP treatment protocols. Standardized delivery systems may facilitate research efforts and provide dosing regimens to help shape best-practice applications of systemic bevacizumab for patients with early-onset or less-severe disease phenotypes. Level of Evidence: 5 Laryngoscope, 131:E1941–E1949, 2021.

AB - Objectives/Hypothesis: The purpose of this study is to develop consensus on key points that would support the use of systemic bevacizumab for the treatment of recurrent respiratory papillomatosis (RRP), and to provide preliminary guidance surrounding the use of this treatment modality. Study Design: Delphi method-based survey series. Methods: A multidisciplinary, multi-institutional panel of physicians with experience using systemic bevacizumab for the treatment of RRP was established. The Delphi method was used to identify and obtain consensus on characteristics associated with systemic bevacizumab use across five domains: 1) patient characteristics; 2) disease characteristics; 3) treating center characteristics; 4) prior treatment characteristics; and 5) prior work-up. Results: The international panel was composed of 70 experts from 12 countries, representing pediatric and adult otolaryngology, hematology/oncology, infectious diseases, pediatric surgery, family medicine, and epidemiology. A total of 189 items were identified, of which consensus was achieved on Patient Characteristics (9), Disease Characteristics (10), Treatment Center Characteristics (22), and Prior Workup Characteristics (18). Conclusion: This consensus statement provides a useful starting point for clinicians and centers hoping to offer systemic bevacizumab for RRP and may serve as a framework to assess the components of practices and centers currently using this therapy. We hope to provide a strategy to offer the treatment and also to provide a springboard for bevacizumab's use in combination with other RRP treatment protocols. Standardized delivery systems may facilitate research efforts and provide dosing regimens to help shape best-practice applications of systemic bevacizumab for patients with early-onset or less-severe disease phenotypes. Level of Evidence: 5 Laryngoscope, 131:E1941–E1949, 2021.

KW - Avastin

KW - Systemic bevacizumab

KW - consensus

UR - http://www.scopus.com/inward/record.url?scp=85099104058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85099104058&partnerID=8YFLogxK

U2 - 10.1002/lary.29343

DO - 10.1002/lary.29343

M3 - Article

C2 - 33405268

AN - SCOPUS:85099104058

SN - 0023-852X

VL - 131

SP - E1941-E1949

JO - Laryngoscope

JF - Laryngoscope

IS - 6

ER -

Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this